Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIncreased wind and flatulence are among the most commonly reported digestive side effects of Wegovy (semaglutide). They tend to appear in the first few weeks of treatment, particularly after a dose increase, because semaglutide slows the rate at which food moves through the gut. For the vast majority of people, the symptoms ease as the body adjusts. Wegovy is a prescription-only medicine, and a prescriber will discuss your full side-effect profile as part of any clinical assessment. The NHS patient information page for semaglutide lists flatulence explicitly among the known gastrointestinal effects.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors in the gut and brain, which reduces appetite and slows gastric emptying. That slowing is useful (it prolongs the feeling of fullness) but it also means food sits in the digestive tract longer than it normally would. Bacteria in the large intestine have more time to ferment undigested carbohydrates, and fermentation produces gas. The result, for a lot of people starting or increasing Wegovy, is noticeably more flatulence.
It is a question our prescribers hear most weeks: whether the wind is a sign something is wrong. Usually it is not. It is the gut reacting to a genuine pharmacological change in motility, not an injury or an intolerance developing. The same mechanism underlies most of Wegovy's other gastrointestinal effects (nausea, loose stools, constipation) because they all trace back to altered transit time. Some people experience a change in the quality of wind as well as the quantity, which is also part of the same picture.
For a broader look at how the medicine works and what the clinical-trial evidence shows, the Wegovy overview on our site covers the mechanism in full.
Timing varies between individuals, but the pattern is fairly consistent. The worst of it tends to arrive in the first one to three weeks after each dose increase, then taper as the gut acclimatises. Most people find the side effects at 0.5mg are milder than those at the initial 0.25mg starter dose, the body has begun to adapt. By the time someone reaches a maintenance dose, the gut has usually settled considerably, though a small proportion of people find some degree of ongoing wind throughout treatment.
Certain foods reliably amplify the problem. Cruciferous vegetables (broccoli, cabbage, cauliflower), legumes, carbonated drinks, and foods high in fructose all produce more fermentation gas under normal circumstances. On Wegovy, with slower transit, their effect is magnified. Eating quickly and swallowing air adds to it. Large meals are harder to process than smaller ones, and since the medicine is reducing appetite anyway, moving to smaller, more frequent portions often helps on both counts.
If you are in the early weeks and finding things difficult, practical tips for the starting phase of Wegovy include specific dietary guidance that many people find reduces GI symptoms meaningfully.
For most people, wind on Wegovy is uncomfortable rather than alarming. That said, there are situations worth taking seriously. Wind accompanied by severe, persistent stomach pain (particularly pain that radiates towards the back) should prompt urgent medical attention, as this pattern can indicate acute pancreatitis, a recognised but infrequent side effect of GLP-1 medicines. The MHRA's Yellow Card scheme is the route for reporting any suspected side effect that concerns you, including ones not listed in the patient information leaflet.
Persistent diarrhoea alongside wind can lead to dehydration, which matters more if you are already eating and drinking less than usual. Signs of dehydration (dark urine, dizziness, a dry mouth) are worth acting on promptly by contacting your prescriber or, if severe, seeking medical care. Flatulence on its own, without these accompanying features, is almost always a nuisance rather than a clinical concern. If it persists beyond several weeks without any sign of settling, a conversation with your prescriber about dose timing or whether the titration schedule can be adjusted is reasonable. You can read more about what to do if wind on Wegovy feels constant.
Neither, exactly. Wind is not an indicator that the medicine is doing its job, results are measured in weight change and metabolic markers over months, not in digestive side effects. Equally, experiencing it does not mean something has gone wrong. It means semaglutide is affecting gut motility in the way it is known to, and your digestive system is still calibrating.
People who experience significant GI side effects early on sometimes assume they are intolerant to the medicine and stop. That is worth discussing with your prescriber before deciding, because the picture at week two is rarely the picture at week eight. Many people who find the first month difficult report that things improve substantially once they are settled on a stable dose.
For anyone considering treatment and wondering about the overall experience of beginning Wegovy, understanding the GI side-effect pattern upfront tends to make the early weeks more manageable. Treatment cost is a practical question too, our Wegovy pricing page sets out what is included in a private prescription at nume. If you'd like to find out whether Wegovy is clinically suitable for you, you can check your eligibility with our prescribers at any time, free of charge.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.